Biswas Ayan, Pan Xueliang, Meyer Melissa, Khanna Savita, Roy Sashwati, Pearson Gregory, Kirschner Richard, Witman Patricia, Faith Esteban Fernandez, Sen Chandan K, Gordillo Gayle M
Columbus, Ohio.
From the Department of Plastic Surgery, the Department of Biomedical Informatics, Center for Biostatistics, the Department of Surgery, and the Divisions of Vascular Surgery and General Surgery, The Ohio State University; and the Department of Pediatrics, the Hemangioma and Vascular Malformation Clinic, and the Department of Pediatrics, Division of Dermatology, Nationwide Children's Hospital.
Plast Reconstr Surg. 2017 Jun;139(6):1277e-1284e. doi: 10.1097/PRS.0000000000003349.
Hemangiomas are unique endothelial cell tumors that involute spontaneously, which makes interpreting their response to therapies difficult. The objective of this work was to identify a potential biomarker in the urine of children with infantile hemangiomas that would facilitate testing new therapies.
A prospective longitudinal study in children with hemangiomas and age-matched healthy controls was performed to determine whether microRNA-126, which is highly abundant in fetal endothelial cells, was more abundant in the urine of affected children. Prospective ultrasound measurements of hemangioma size and blood flow velocity were obtained as secondary endpoints to document longitudinal changes in untreated hemangiomas.
Urinary microRNA-126 levels were significantly elevated in children with proliferating hemangiomas, and relative levels of urinary microRNA abundance correlated with hemangioma size. Hemangiomas had elevated levels of microRNA abundance compared with healthy controls. Ultrasound data revealed that hemangioma proliferation typically stopped between 6 and 9 months of age. When hemangioma proliferation stopped, urinary microRNA-126 levels in children with hemangiomas dropped to levels observed in healthy age-matched controls.
These are the first reported results to identify a potential microRNA biomarker in the urine of children with hemangiomas. Measurement of urinary levels of microRNA-126 could potentially be used to monitor hemangioma response to therapies.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Diagnostic, II.
血管瘤是一种独特的内皮细胞瘤，可自发消退，这使得解读其对治疗的反应变得困难。本研究的目的是在患有婴儿血管瘤的儿童尿液中鉴定一种潜在的生物标志物，以促进新疗法的测试。
对患有血管瘤的儿童和年龄匹配的健康对照进行了一项前瞻性纵向研究，以确定在胎儿内皮细胞中高度丰富的微小RNA-126在患病儿童尿液中是否更丰富。作为记录未经治疗的血管瘤纵向变化的次要终点，获得了血管瘤大小和血流速度的前瞻性超声测量结果。
增殖期血管瘤患儿尿中微小RNA-126水平显著升高，尿中微小RNA丰度的相对水平与血管瘤大小相关。与健康对照相比，血管瘤的微小RNA丰度水平升高。超声数据显示，血管瘤增殖通常在6至9个月龄时停止。当血管瘤增殖停止时，患有血管瘤的儿童尿中微小RNA-126水平降至年龄匹配的健康对照者中观察到的水平。
这些是首次报道的在患有血管瘤的儿童尿液中鉴定潜在微小RNA生物标志物的结果。测量尿中微小RNA-126水平可能用于监测血管瘤对治疗的反应。
临床问题/证据水平：诊断性，II级
